Overexpression of collagen VI α3 in gastric cancer

Xie,Xiaojun; Liu,Xiaosun; Zhang,Qing; Yu,Jiren

doi:10.3892/ol.2014.1910

Overexpression of collagen VI α3 in gastric cancer

Authors:
- Xiaojun Xie
- Xiaosun Liu
- Qing Zhang
- Jiren Yu
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: February 25, 2014 https://doi.org/10.3892/ol.2014.1910
Pages: 1537-1543

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Collagen VI is significant in the progression of numerous types of cancer. Type VI collagen consists of three α‑chains and collagen VI α3 (COL6A3) encodes the α3 chain. The overexpression of COL6A3 has been demonstrated to correlate with high-grade ovarian cancer and contributes to cisplatin resistance; however, its role in human gastric cancer (GC) remains unclear. Using microarray meta‑analysis, COL6A3 was observed to be frequently overexpressed in the GC tissues, furthermore, this overexpression was identified in five GC cell lines. A microarray‑based co‑expression network analysis was conducted and identified a total of 62 genes that were co‑expressed with COL6A3, with the majority of the genes being involved in cancer‑related processes, such as cell differentiation, migration and adhesion. Network analysis of these 62 genes demonstrated that fibronectin 1, a well-characterized oncogene, was located at the center of the COL6A3 co-expression network. Therefore, COL6A3 may act as an oncogene in human GC and the antagonism of COL6A3 may be an effective therapeutic treatment for GC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Bönnemann CG: The collagen VI-related myopathies: muscle meets its matrix. Nat Rev Neurol. 7:379–390. 2011.PubMed/NCBI
3	Iyengar P, Espina V, Williams TW, et al: Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest. 115:1163–1176. 2005. View Article : Google Scholar
4	Schäffler A, Schölmerich J and Buechler C: Mechanisms of disease: adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab. 3:345–354. 2007.
5	Sherman-Baust CA, Weeraratna AT, Rangel LB, et al: Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell. 3:377–386. 2003. View Article : Google Scholar
6	Aumailley M, Mann K, von der Mark H and Timpl R: Cell attachment properties of collagen type VI and Arg-Gly-Asp dependent binding to its alpha 2(VI) and alpha 3(VI) chains. Exp Cell Res. 181:463–474. 1989. View Article : Google Scholar
7	Ismail RS, Baldwin RL, Fang J, Browning D, Karlan BY, Gasson JC and Chang DD: Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res. 60:6744–6749. 2000.
8	Thorsen K, Sørensen KD, Brems-Eskildsen AS, et al: Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics. 7:1214–1224. 2008. View Article : Google Scholar
9	Rhodes DR, Yu J, Shanker K, et al: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA. 101:9309–9314. 2004. View Article : Google Scholar
10	Xing C, Zhou W, Ding S, et al: Reversing effect of ring finger protein 43 inhibition on malignant phenotypes of human hepatocellular carcinoma. Mol Cancer Ther. 12:94–103. 2013. View Article : Google Scholar
11	Chen X, Leung SY, Yuen ST, et al: Variation in gene expression patterns in human gastric cancers. Mol Biol Cell. 14:3208–3215. 2003. View Article : Google Scholar : PubMed/NCBI
12	Cho JY, Lim JY, Cheong JH, et al: Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res. 17:1850–1857. 2011. View Article : Google Scholar : PubMed/NCBI
13	D’Errico M, de Rinaldis E, Blasi MF, et al: Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. Eur J Cancer. 45:461–469. 2009.PubMed/NCBI
14	Wang Q, Wen YG, Li DP, et al: Upregulated INHBA expression is associated with poor survival in gastric cancer. Med Oncol. 29:77–83. 2012. View Article : Google Scholar : PubMed/NCBI
15	Fierro AC, Vandenbussche F, Engelen K, Van de Peer Y and Marchal K: Meta analysis of gene expression data within and across species. Curr Genomics. 9:525–534. 2008. View Article : Google Scholar
16	Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI
17	Pfaff M, Aumailley M, Specks U, Knolle J, Zerwes HG and Timpl R: Integrin and Arg-Gly-Asp dependence of cell adhesion to the native and unfolded triple helix of collagen type VI. Exp Cell Res. 206:167–176. 1993. View Article : Google Scholar : PubMed/NCBI
18	Burg MA, Tillet E, Timpl R and Stallcup WB: Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules. J Biol Chem. 271:26110–26116. 1996. View Article : Google Scholar : PubMed/NCBI
19	Perris R, Kuo HJ, Glanville RW and Bronner-Fraser M: Collagen type VI in neural crest development: distribution in situ and interaction with cells in vitro. Dev Dyn. 198:135–149. 1993. View Article : Google Scholar : PubMed/NCBI
20	Gardina PJ, Clark TA, Shimada B, et al: Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics. 7:3252006. View Article : Google Scholar : PubMed/NCBI
21	Arafat H, Lazar M, Salem K, et al: Tumor-specific expression and alternative splicing of the COL6A3 gene in pancreatic cancer. Surgery. 150:306–315. 2011. View Article : Google Scholar : PubMed/NCBI
22	Smith DD, Saetrom P, Snøve O Jr, Lundberg C, Rivas GE, Glackin C and Larson GP: Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation. BMC Bioinformatics. 9:632008. View Article : Google Scholar
23	Rybaczyk LA, Bashaw MJ, Pathak DR and Huang K: An indicator of cancer: downregulation of monoamine oxidase-A in multiple organs and species. BMC Genomics. 9:1342008. View Article : Google Scholar
24	Verrecchia F, Chu ML and Mauviel A: Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem. 276:17058–17062. 2001. View Article : Google Scholar : PubMed/NCBI
25	Torbenson M, Wang J, Choti M, Ashfaq R, Maitra A, Wilentz RE and Boitnott J: Hepatocellular carcinomas show abnormal expression of fibronectin protein. Mod Pathol. 15:826–830. 2002. View Article : Google Scholar : PubMed/NCBI
26	Warawdekar UM, Zingde SM, Iyer KS, Jagannath P, Mehta AR and Mehta NG: Elevated levels and fragmented nature of cellular fibronectin in the plasma of gastrointestinal and head and neck cancer patients. Clin Chim Acta. 372:83–93. 2006. View Article : Google Scholar : PubMed/NCBI
27	Waalkes S, Atschekzei F, Kramer MW, et al: Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer. 10:5032010. View Article : Google Scholar : PubMed/NCBI